The government plans to re-evaluate the full reimbursement of long-term conditions: what does this really entail ?

The long-term illness (LTI) scheme has long been a cornerstone of the French public health system, ensuring 100% reimbursement of care and treatments for nearly 14 million French people suffering from chronic or severe diseases. This mechanism, which relies on Social Security and Health Insurance, guarantees extensive coverage and easier access to care, particularly for pathologies such as diabetes, cancers, or Crohn’s disease. However, faced with a constrained budgetary context, the government, driven by a desire for significant savings estimated in the billions of euros, is now reconsidering this system. This reflection centers around the crucial issue of fully covered reimbursements, a historic pillar of French social protection.

Prime Minister François Bayrou has opened the debate by announcing an intention to restrict 100% reimbursement for certain treatments associated with LTIs, particularly targeting medications that are not directly related to the diagnosed disease. This announcement highlights not only the need for financial adjustment but also critiques of medical and administrative practices, where abuse or errors in categorizing care could inflate costs. The Ministry of Health and managing bodies such as the Primary Health Insurance Fund (CPAM) are ambivalent between maintaining a system deemed protective and implementing necessary corrective measures.

From this perspective, it is worth noting that this approach aims not only to reduce costs but also to optimize expenses within a more responsible framework, aligned with recommendations from mutual insurance entities and supplementary health plans. The review could include stricter criteria on the Reimbursement Plan and foster closer cooperation among healthcare professionals, pharmacists, and supplementary insurances. The potential impact of this reform raises concerns among vulnerable patients but also sparks the debate on finding the right balance between solidarity and economic sustainability in a context where costs related to chronic diseases continue to rise.

The long-term illness (LTI) scheme: comprehensive and essential coverage

The long-term illness scheme is an essential component of the French public health system, designed to guarantee chronic disease patients 100% coverage of care related to their condition. Managed by Social Security and facilitated via the AMELI platform, this mechanism aims to remove financial barriers for often heavy and prolonged treatments.

More than 40 pathologies are now covered, ranging from metabolic diseases like diabetes to severe neurological disorders and cancers. In 2022, nearly 14 million people benefited from this measure, representing about one-fifth of the French population. The system does not limit itself to hospitalizations or consultations; it also includes medications, nursing care, and sometimes necessary medical devices for daily patient monitoring.

This system operates based on strict medical criteria according to a list established by the Ministry of Health. Recognition of a LTI requires a detailed medical certificate, an obligatory visit to the Primary Health Insurance Fund (CPAM), which grants the status and manages the coverage. This organization ensures that only serious or chronic conditions justify this full coverage.

It is important to highlight the tangible benefits of this system:

• 📌 Facilitated access to costly medications and treatments, especially for chemotherapies or antidiabetic treatments, with no out-of-pocket expenses.
• 📌 Reduction of social inequalities by limiting economic obstacles to long-term care.
• 📌 Enhanced medical coordination among specialists, general practitioners, and paramedical teams.
• 📌 Psychological support and assistance for patients and their families, through care networks and recognition of sometimes associated disabilities.

Chronic disease	Approximate number of beneficiaries	Type of coverage	Examples of reimbursed treatments
Diabetes	4 million	100% reimbursement	Insulin, glucometers, specialized consultations
Cancer	2 million	100% reimbursement	Chemotherapies, radiotherapies, targeted medications
Crohn’s Disease	250,000	100% reimbursement	Anti-inflammatory drugs, immunosuppressants, gastro consultations
Disabling stroke	150,000	100% reimbursement	Rehabilitation, nursing care, anticoagulant treatments

This comprehensive coverage is a major achievement of the system and is already integrated into supplementary health insurance plans, which often adapt to this already extensive coverage. These mutual insurance companies and supplementary insurers can thus extend their support to other costs not covered by the Health Insurance.

Necessary reevaluation: the financial and social stakes of 100% reimbursement for LTIs

Faced with a sharply rising expenditure trajectory, the government sees significant savings potential in the LTI system. The Prime Minister’s plan, which foresees a general reduction of 5 billion euros in social spending, specifically targets the full reimbursement of care related to long-term illnesses.

According to reported data, these coverages concern more than 20% of the adult population, representing a major challenge for Social Security and the Health Insurance budget. The risk of exceeding expenditure ceilings is real amid demographic aging and increasing chronic disease cases.

<p Moreover, voices within health organizations and professional unions criticize certain abuses observed in the classification and reimbursement of medications. Pierre-Olivier Variot, President of the Union of Pharmacy Syndicates (USPO), emphasizes that:

• 💊 some medications, not directly related to the diagnosed disease in LTI, are nonetheless reimbursed at 100%,
• 💊 hospital-based doctors sometimes classify treatments too broadly,
• 💊 conversely, errors omit costly essential medications, impacting patients.

This situation raises questions about the Reimbursement Plan and suggests withdrawing the LTI status in certain cases, notably for patients in complete remission, thus prompting the following questions:

1. 🔍 How to ensure rational and targeted use of reimbursements?
2. 🔍 What safeguards for vulnerable patients to prevent treatment abandonment?
3. 🔍 What role for doctors and pharmacists in regulating coverage?

In response, the Primary Health Insurance Fund and the Ministry of Health are currently exploring measures to combat fraud and better control reimbursements, while respecting the fundamental right to health. Information campaigns targeting professionals are also planned to remind them of the strict criteria of the system.

Reevaluation stakes	Expected impacts	Planned measures
Reduction of social expenses	Savings up to 5 billion euros	Cumulative restrictions on reimbursements outside direct links
Fight against abuses and frauds	Better resource management	Enhanced controls and prescriber training
Preservation of solidarity	Protection of genuinely ill patients	Withdrawal of LTI status for stabilized cases

This revision has now become an integral part of the public debate and budget negotiations, raising concerns among several patient associations and health organizations. To better understand the concrete implications, it is essential to examine the mechanisms, stakeholders, and consequences of such a reform.

Diseases concerned by long-term illnesses and eligibility criteria

The LTI scheme covers an official list of conditions recognized by the Ministry of Health. This list includes more than forty diseases across various medical fields:

• 🧬 Endocrine and metabolic diseases (diabetes, hypothyroidism)
• 🧠 Neurological and neurodegenerative diseases (multiple sclerosis, Parkinson’s)
• 🫀 Severe cardiovascular diseases (disabling stroke, heart failure)
• 🩺 Cancers and leukemias
• 🦠 Infectious long-term diseases (chronic hepatitis, HIV)
• 🦷 Chronic inflammatory diseases (rheumatoid arthritis, Crohn’s disease)

To be eligible for 100% coverage, several conditions must be met:

1. 📄 Submission of a detailed medical certificate, justifying the severity of the disease and the prolonged or disabling nature of care.
2. 📋 Processing of the file by the local Primary Health Insurance Fund, which decides on granting LTI status.
3. 🔄 Regular updates of the medical file, including annual visits to ensure follow-up and adapt coverage.

The AMELI system centralizes these administrative procedures, offering patients simplified access to their rights and reimbursements. Collaboration with healthcare professionals is key to ensuring coherence in coverage.

Medical field	Examples of pathologies	Estimated number of patients	Required follow-up
Endocrinology	Type 1 and 2 diabetes	4 million	Regular blood tests and therapeutic adjustments
Oncology	Solid and hematological cancers	2 million	Chemotherapy, radiotherapy, specialized consultations
Neurology	Multiple sclerosis, disabling stroke	650,000	Rehabilitation, symptomatic treatment, neurological follow-up
Gastroenterology	Crohn’s disease, chronic hepatitis	400,000	Anti-inflammatory treatments, regular assessments

These strict criteria aim to protect the viability of the system while providing quality medical follow-up tailored to patients’ evolving needs. A delicate balance is sought between maximum support and economic efficiency.

Impact of the review on eligibility criteria

The planned modification in managing full reimbursement could lead to a revision of access criteria. Notably, partial or complete withdrawal of LTI status might be considered for some patients in stable phase or full remission. This tightening raises questions about the balance between rigorous medical evaluation and social protection.

Impacts for patients: concerns and possible adaptations

The potential revision of full reimbursement raises significant concerns among affected populations. These long-term illnesses often affect vulnerable or fragile individuals for whom easy access to care without out-of-pocket expenses is crucial for maintaining health and quality of life.

Numerous associations and bodies such as the League Against Cancer have expressed fears that treatment abandonment could occur if coverage is reduced. This concern is based on:

• ⚠️ The possible increase in out-of-pocket costs for essential treatments.
• ⚠️ Increased risks of inequalities in access to care, especially in rural or disadvantaged areas.
• ⚠️ Stress and anxiety related to the loss of financial security in healthcare matters.

Despite these concerns, some patients and professionals emphasize the need for constructive dialogue to adapt the system and avoid administrative errors or abuses. Several options are being studied:

• ✅ Strengthen communication between the Primary Health Insurance Fund, doctors, and patients.
• ✅ Implement systematic evaluation of reimbursed treatments based on their direct link to the pathology.
• ✅ Promote personalized care plans integrating supplementary health insurance and local mutual insurance.

This dialogue is essential to prevent the reform from further weakening already ill individuals. Healthcare professionals are called upon to play a greater role in adapting prescriptions and monitoring treatments.

Potential consequences	Concerned patients	Proposed adaptation measures
Increase in out-of-pocket costs	Older adults and chronic illness sufferers	Optimization of supplementary health insurance and social assistance
Care abandonment	Vulnerable populations	Enhanced support from health organizations
Territorial inequalities	Rural and disadvantaged areas	Creation of specific programs and localized monitoring

The role of healthcare professionals in managing LTI reimbursements

General practitioners, specialists, and pharmacists are key players in the proper functioning of the LTI system. Their responsibility in selecting treatments and ensuring prescription quality largely determines the reliability of reimbursements and the fight against abuse.

According to Pierre-Olivier Variot, vigilance at the hospital level must be strengthened, as there has been a trend to classify medications under the 100% LTI category, thereby increasing the Social Security deficit. Conversely, errors in omitting coverage for essential treatments are also pointed out.

To improve this oversight, the following approaches are being considered:

• 🏥 Enhanced training and regular updates for prescribers on LTI criteria and reimbursement rules.
• 📊 Use of digital tools, including AMELI, to support real-time prescription and detect anomalies.
• 🤝 Increased cooperation between pharmacists, doctors, and health insurance organizations to better control prescriptions.

Stakeholder	Key role	Planned actions
General practitioners	Assessment of pathology and prescription	Ongoing training and verification of links with LTI
Hospital specialists	Monitoring of complex treatments	Strengthening controls and internal audits
Community pharmacists	Dispensing and verifying prescriptions	Reporting inconsistencies and collaborating with CPAM

This multifaceted cooperation is part of a comprehensive approach aimed at preserving access to care while strengthening the economic sustainability of the system, within the broader framework of policies led by the Ministry of Health.

The stakes for supplementary health insurers in the face of the LTI reform

Mutual insurance companies and complementary insurers play an indispensable relay role with patients to cover expenses not covered by Social Security, particularly in the event of changes to the LTI scheme. Their strategic position is critical in this uncertain context.

In the face of a possible reduction in full coverage, mutual insurers will need to adapt by offering enhanced or specialized plans for chronically ill patients. In some cases, these insurers may be encouraged to review their reimbursement grids and modify contributions, directly impacting policyholders.

Here are the main challenges faced by health insurance organizations:

• 💼 Adapting offerings to remain attractive and competitive in a sensitive market.
• 💼 Managing financial risk related to a potential increase in out-of-pocket costs.
• 💼 Strengthening collaboration with Social Security and healthcare institutions to optimize care pathways.
• 💼 Implementing prevention and support actions to limit complications and costly hospitalizations.

Mutual insurance stakes	Expected actions	Impact on members
Revaluation of guarantees	Creation of specific LTI options	Potential increase in contributions
Risk management	Detailed analysis of patient files	Personalized reimbursements
Supporting patients	Prevention programs and follow-up	Improved quality of life

These changes, while challenging, could help establish a more sustainable model aligned with economic and health realities. This evolution is closely monitored by entities such as the Primary Health Insurance Fund and the Ministry of Health, as well as sector professionals.

Perspectives and risks related to the reform of LTI reimbursements

This proposed reform by the government generates debates and controversies across various spheres. Beyond financial considerations, it is also an ethical and social issue of primary importance, balancing financial flexibility with patient protection.

Supporters of the current system emphasize that partial or total removal of 100% reimbursement could:

• ⚖️ Increase inequalities in healthcare access, especially among vulnerable populations,
• ⚖️ Lead to treatment abandonment due to financial concerns,
• ⚖️ Place increased burden on associations and health organizations to compensate for gaps.

Conversely, reform advocates highlight:

• 📉 The need to control public expenditure to ensure system sustainability,
• 📉 Targeted reduction of abuses to improve efficiency,
• 📉 Redirecting aid toward the most severe or active cases.

Faced with these issues, public debate intensifies, and the government must reconcile divergent interests while maintaining citizens’ trust in the healthcare system. The decisions made will have long-term implications for the country’s social and health policies.

Argument	For the reform	Against the reform
Budgetary savings	Estimated reduction of 5 billion euros	Risk of higher indirect costs on public health
Access to care	Better allocation of resources	Fragilization of chronically ill patients
Social solidarity	Targeted optimization	Compromise of equality principle

Health organizations, notably the Primary Health Insurance Fund, continue to influence the debate with proposals aimed at a pragmatic balance, where solidarity remains fundamental while adjusting the financial mechanisms to economic realities.

Monitoring and digital tools to ensure optimized reimbursements

The integration of new digital technologies into the LTI system presents a significant opportunity to make the reimbursement plan more transparent, efficient, and reliable. The AMELI portal plays a crucial role in this context, notably by allowing:

• 📱 The digital management of files and rapid updating of information on pathologies and treatments.
• 📱 Automated control of prescriptions with alerts in case of anomalies or abuse.
• 📱 Facilitated communication between doctors, pharmacists, patients, and social security organizations.

Moreover, supplementary applications are being developed to support professionals and ensure daily monitoring of patients with chronic diseases, thereby reducing errors and encouraging better adherence to therapy.

Digital tool	Functionality	Expected impact
AMELI	The official Social Security platform	Centralization of data and real-time monitoring
Automatic alerts	Rapid detection of abnormal reimbursements	Reduction of abuses
Patient mobile apps	Personalized follow-up and intake reminders	Improved adherence

These innovations are key leverage points to support reform in modernizing the public health system and enhancing patients’ quality of life.

FAQ: What you need to know about the reassessment of LTI reimbursements

• ❓ What is the LTI status?

  The LTI status recognizes a chronic or severe disease justifying 100% reimbursement of care related to this condition.

• ❓ Why does the government want to reassess LTI reimbursements?

  To control rapidly increasing social expenses and limit potential abuses in reimbursements.

• ❓ What impacts for patients?

  A possible increase in out-of-pocket costs, especially for treatments not directly related to the disease, with a risk of treatment abandonment if no complementary support is provided.

• ❓ How will doctors and pharmacists be involved?

  They will need to reinforce rigor in prescribing and dispensing treatments, cooperating with CPAM and health insurance organizations.

• ❓ What role for supplementary health insurers?

  Mutual insurers will need to adapt by proposing personalized offers and supporting patients in financing treatments not covered.

For more detailed information, please consult the following articles:

• Budget 2026: Long-term illnesses (LTI) in François Bayrou’s sights
• Budget 2026: savings, what is the LTI scheme targeted by François Bayrou?
• Budget: what does the 100% reimbursement for chronically ill patients entail that Bayrou wants to revisit?
• Health insurance reimbursement: operation and prospects
• Cooperation between insurance and mutuals to fight fraud

Source: www.capital.fr